HomeCompareMAHMF vs ABBV

MAHMF vs ABBV: Dividend Comparison 2026

MAHMF yields 0.87% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAHMF wins by $2.76M in total portfolio value· pulled ahead in Year 6
10 years
MAHMF
MAHMF
● Live price
0.87%
Share price
$33.50
Annual div
$0.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.87M
Annual income
$2,346,203.74
Full MAHMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MAHMF vs ABBV

📍 MAHMF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMAHMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MAHMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MAHMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MAHMF
Annual income on $10K today (after 15% tax)
$73.58/yr
After 10yr DRIP, annual income (after tax)
$1,994,273.18/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MAHMF beats the other by $1,973,217.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MAHMF + ABBV for your $10,000?

MAHMF: 50%ABBV: 50%
100% ABBV50/50100% MAHMF
Portfolio after 10yr
$1.48M
Annual income
$1,185,487.75/yr
Blended yield
79.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MAHMF
No analyst data
Altman Z
2.2
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MAHMF buys
0
ABBV buys
0
No recent congressional trades found for MAHMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMAHMFABBV
Forward yield0.87%3.06%
Annual dividend / share$0.29$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$2.87M$102.3K
Annual income after 10y$2,346,203.74$24,771.77
Total dividends collected$2.80M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MAHMF vs ABBV ($10,000, DRIP)

YearMAHMF PortfolioMAHMF Income/yrABBV PortfolioABBV Income/yrGap
1$10,873$173.13$11,550$430.00$677.00ABBV
2$11,986$351.87$13,472$627.96$1.5KABBV
3$13,550$725.03$15,906$926.08$2.4KABBV
4$16,031$1,532.03$19,071$1,382.55$3.0KABBV
5$20,541$3,387.83$23,302$2,095.81$2.8KABBV
6← crossover$30,092$8,113.90$29,150$3,237.93+$942.00MAHMF
7$54,418$22,218.67$37,536$5,121.41+$16.9KMAHMF
8$133,328$75,101.04$50,079$8,338.38+$83.2KMAHMF
9$486,594$343,932.99$69,753$14,065.80+$416.8KMAHMF
10$2,866,859$2,346,203.74$102,337$24,771.77+$2.76MMAHMF

MAHMF vs ABBV: Complete Analysis 2026

MAHMFStock

Mahindra & Mahindra Limited provides mobility products and farm solutions in India and internationally. The company operates through Automotive, Farm Equipment, Financial Services, Hospitality, Real Estate, and Others segments. It offers parts and assemblies for aerospace and defense sectors; passenger and commercial vehicles, trucks, buses, vans, cars, utility vehicles, and electric vehicles; watercrafts; motorcycles, scooters, and mopeds; construction equipment, such as backhoe loaders under the Mahindra EarthMaster brand; and road construction equipment comprising motor graders under the Mahindra RoadMaster brand. The company also provides land and naval systems, defense electronics, and security consulting services for defense industry; pre-owned car and car services; and farm equipment. In addition, it operates M2All, an e-commerce platform for various portfolio of products; approximately 100 resorts; and solar PV projects. Further, the company offers financial services comprising retail and other loans, SME finance, housing finance, mutual funds, and life and non-life insurance broking services, as well as vehicle and equipment financing; logistics services; information security and risk management, engineering consulting, and business process management consulting services; information technology services; and power backup solutions, such as diesel and gas generators. Additionally, it engages in the development, management, and operation of commercial complexes; sale of timeshare and vacation ownership; and making, processing, and trading of steel for automotive, non-automotive, and power industries. The company was incorporated in 1945 and is based in Mumbai, India.

Full MAHMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MAHMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MAHMF vs SCHDMAHMF vs JEPIMAHMF vs OMAHMF vs KOMAHMF vs MAINMAHMF vs JNJMAHMF vs MRKMAHMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.